Quoin Pharmaceuticals Announces Private Placement Financing of Up to $50 Million on August 31, 2026 ADSs clinical development Dilution technique financing characteristics Netherton Syndrome private placement QNRX QRX003 Quoin Pharmaceuticals +
RAPT Therapeutics Announces Proposed Public Offering of Common Stock on October 23, 2025 Biological Factors conditions Dilution technique Gross (qualifier value) Immunology Market Pricing public entity RAPT +